Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of PM8002 plus chemotherapy as first-line treatment for unresectable hepatocellular carcinoma
CTR20221166Phase 2Active
- Sponsor
- Biotheus
- Start
- Sep 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of pumitamig in hepatocellular carcinoma (HCC), sponsored by Biotheus. Started Sep 2022; status: active.
02
Drugs
pumitamig
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20221166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221166.